Drug Profile
VM 200
Alternative Names: VM200Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Case Western Reserve University
- Developer Vision Medicines
- Class Amines; Eye disorder therapies; Small molecules
- Mechanism of Action Aldehyde inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inborn error metabolic disorders; Macular degeneration; Sjogren-Larsson syndrome; Stargardt disease
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for preclinical development in Inborn-error-metabolic-disorders in USA (PO)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Macular-degeneration in USA (PO)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Sjogren-Larsson syndrome in USA (PO)